Granegis

Granegis is a prescription medication that contains the active ingredient granisetron, supplied as oral tablets. It belongs to the 5-HT3 receptor antagonist class and is used to prevent nausea and vomiting associated with chemotherapy and surgery. Marketed in the European Union, Granegis works by selectively blocking serotonin receptors in the central nervous system, helping to control emesis without requiring injection.

Granegis is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings. It is commonly prescribed for patients undergoing cancer therapy or surgical procedures.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) - Management of postoperative nausea and vomiting (PONV) - Adjunct therapy for radiation‑induced emesis - Use in patients who have not responded adequately to other antiemetics - Supportive care to improve comfort during anti‑cancer treatment

Granegis may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are uncommon but require medical attention.

Common: - Headache - Constipation - Diarrhea - Fatigue or drowsiness - Dizziness - Flushing

Serious: - Severe allergic reaction (rash, itching, swelling, difficulty breathing) - Cardiac arrhythmia or prolonged QT interval - Persistent severe abdominal pain - Signs of serotonin syndrome when combined with serotonergic agents

Before starting Granegis, certain health considerations should be reviewed to ensure safe use.

- Assess cardiac history, especially QT prolongation risk - Review concomitant medications that affect heart rhythm - Use cautiously in patients with hepatic impairment - Monitor for signs of allergic reactions during initial dosing - Discuss pregnancy and breastfeeding status with a healthcare professional - Adjust dose in elderly patients if renal function is reduced

Granegis can interact with other drugs, influencing its effectiveness or safety profile.

Avoid: - Other 5‑HT3 antagonists or drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics) - Strong CYP3A4 inhibitors that may increase granisetron levels

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, or tramadol (risk of serotonin syndrome) - Medications that also cause constipation (may exacerbate gastrointestinal effects) - Drugs metabolized by the same hepatic pathways (monitor for altered plasma concentrations)